Hepatitis B Screening for STI Testing
For STI screening, order hepatitis B surface antigen (HBsAg) as the initial screening test, followed by a confirmatory neutralizing test if HBsAg is repeatedly reactive. 1, 2
Recommended Testing Approach
The screening algorithm for hepatitis B in the STI context is straightforward:
Initial Screening Test
- HBsAg (Hepatitis B surface antigen) is the primary screening test 1
- This single test identifies both acute and chronic HBV infection
- Must use FDA-approved HBsAg tests 1
Confirmatory Testing
- If HBsAg is repeatedly reactive, perform a neutralizing confirmatory test cleared by the FDA 2
- This step is critical to rule out false-positive results
Additional Serologic Panel (After Positive HBsAg)
Once HBsAg is confirmed positive, order a complete serologic panel to determine infection stage and guide management 2:
- Total anti-HBc (antibody to hepatitis B core antigen)
- IgM anti-HBc (distinguishes acute from chronic infection)
- Anti-HBs (antibody to surface antigen)
The interpretation is algorithmic:
- HBsAg positive + IgM anti-HBc positive = Acute infection
- HBsAg positive + total anti-HBc positive + IgM anti-HBc negative = Chronic infection
- HBsAg positive + anti-HBc negative = Early acute infection (within 18 days)
Who Needs Screening in STI Settings
The 2021 CDC STI Treatment Guidelines specifically identify high-risk populations requiring hepatitis B screening 2:
- Men who have sex with men
- Persons who inject drugs (current or past)
- Persons with HIV infection
- Sex partners of HBsAg-positive persons
- Persons with history of multiple sex partners or other STIs
Important update: The 2023 CDC recommendations now advocate for universal hepatitis B screening at least once for all adults aged ≥18 years using three tests (HBsAg, anti-HBc, anti-HBs), and anyone requesting testing should receive it regardless of disclosed risk 3. However, for focused STI screening in clinical practice, the HBsAg-first approach remains the standard.
Screening Intervals for Ongoing Risk
For patients with continued risk factors (active injection drug use, men who have sex with men), periodic HBsAg screening is recommended even if initial results are negative 1. The exact interval is not rigidly defined but should be based on ongoing risk assessment.
Critical Pitfalls to Avoid
Don't skip the confirmatory test: Repeatedly reactive HBsAg results must be confirmed with a neutralizing test to avoid false-positive diagnoses 2
Don't order unnecessary tests upfront: Starting with HBsAg alone is cost-effective; the complete serologic panel is only needed after a positive result 4
Don't forget co-infection testing: All HBsAg-positive persons should be tested for HIV, syphilis, gonorrhea, and chlamydia 2
Don't rely on self-reported vaccination status: Sexual behavior and vaccination history are not reliable for risk stratification in STI settings 5
What NOT to Order Initially
Avoid ordering these tests as initial screening in the STI context:
- Anti-HBc alone (can indicate multiple scenarios and requires additional testing)
- Anti-HBs alone (only indicates immunity, not active infection)
- Complete hepatitis B panels on everyone (wasteful and unnecessary) 4
The evidence strongly supports a streamlined approach: HBsAg first, confirm if positive, then complete the panel to stage the infection. This maximizes diagnostic yield while minimizing unnecessary testing and costs.